Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

To evaluate psychomotor development in PWS infants and toddlers during GH treatment compared to randomized controls.

Why It Was Studied

Prader-Willi syndrome (PWS) is a neurogenetic disorder characterized by muscular hypotonia, psychomotor delay, feeding difficulties and failure to thrive in infancy.

Research on the effects of GH on psychomotor development in infants with PWS is limited.

Who Took Part

By PubMed's age tags, the people studied were infants and young children, both men and women.

Data were converted to percentage of expected development for age (%ed), and changes during follow-up were calculated.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Forty-three PWS infants were evaluated at baseline.

What Was Measured

PubMed files the paper under topics including Body Composition, Growth Hormone, Prader-Willi Syndrome and Psychomotor Disorders.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.